Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal analysis of cognitive function in patients treated with postoperative radiotherapy for grade 2 and 3 IDH mutant diffuse glioma.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 1 Jun 2025

Jaspers J P M, Romero A Méndez, Yaakoubi A El, van Werkhoven E, Nout R A, van den Bent M J, Satoer D

Abstract excerpt

BACKGROUND: Postoperative radiotherapy and chemotherapy improve survival in IDH mutant diffuse glioma. We investigated whether neurocognitive function declines over time, and whether mean dose to the brain outside of CTV (mean brain dose) is related to neurocognitive function. PATIENTS AND METHODS: Patients that underwent resection and postoperative radiotherapy for grade 2 or 3 IDH mutant diffuse glioma were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cognition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Longitudinal Studies

Share to Neoplasm Grading

Share to Neuropsychological Tests

Share to Radiotherapy Dosage

Source

Identifiers

PMID: 40090418
DOI: 10.1016/j.radonc.2025.110847

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal analysis of cognitive function in patients treated with postoperative radiotherapy for grade 2 and 3 IDH mutant diffuse glioma.PMID 40090418Read ↗

Neurocognitive functioning, seizure control, and return to work after awake surgery with or without adjuvant therapy in IDH-mutant grade 3 diffuse gliomas.Semantic proximity Read ↗

Survival, late toxicity and ability to return to work after proton radiotherapy for low grade gliomasSemantic proximity Read ↗

Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.Semantic proximity Read ↗

Analysis of safety and efficacy of proton radiotherapy for IDH-mutated glioma WHO grade 2 and 3.Semantic proximity Read ↗

Cognitive phenotypes: Unraveling the heterogeneity in cognitive dysfunction among patients with primary brain tumors receiving radiotherapy.Semantic proximity Read ↗

Long-term autonomy, professional activities, cognition, and overall survival after awake functional-based surgery in patients with IDH-mutant grade 2 gliomas: a retrospective cohort studySemantic proximity Read ↗

Reliable cognitive changes the first year following guideline-based treatment of isocitrate dehydrogenase mutated gliomas: A longitudinal multicenter study.Semantic proximity Read ↗

Predicting Late Radiation-Associated Neurocognitive and Endocrine Toxicity in Patients with Brain TumorsSemantic proximity Read ↗

Neurocognitive and Resting-State Functional Magnetic Resonance Imaging Changes in Patients With Diffuse Gliomas After Chemoradiation Therapy.Semantic proximity Read ↗

Impact of APOE Genotype on Neurocognition Following Conformal Whole Brain Radiotherapy for Brain Metastases: A Post hoc Analysis of Phase II Randomized TrialSemantic proximity Read ↗

Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.Semantic proximity Read ↗

Neurocognitive functioning and quality of life in patients receiving radiotherapy for intracranial meningiomas. Systematic reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.